{"blog": [], "keywords": [{"value": "Mylan Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Epinephrine (Drug)", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Medical Devices", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Bresch, Heather", "name": "persons", "rank": "4", "is_major": "Y"}, {"value": "Prices (Fares, Fees and Rates)", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "House Committee on Oversight and Government Reform", "name": "organizations", "rank": "6", "is_major": "N"}, {"value": "Allergies", "name": "subject", "rank": "7", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "9", "is_major": "Y"}], "web_url": "http://www.nytimes.com/2016/09/22/business/mylan-chief-to-insist-epipen-is-priced-fairly-at-house-hearing.html", "document_type": "article", "byline": {"person": [{"lastname": "THOMAS", "firstname": "Katie", "role": "reported", "organization": "", "rank": 1}], "original": "By KATIE THOMAS"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/09/22/business/22MYLAN/22MYLAN-thumbWide.jpg", "legacy": {"wide": "images/2016/09/22/business/22MYLAN/22MYLAN-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/09/22/business/22MYLAN/22MYLAN-articleLarge.jpg", "legacy": {"xlarge": "images/2016/09/22/business/22MYLAN/22MYLAN-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/09/22/business/22MYLAN/22MYLAN-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/09/22/business/22MYLAN/22MYLAN-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1004", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Heather Bresch, the chief executive of Mylan, told a skeptical House panel that her company had struck a balance between price and access.", "pub_date": "2016-09-22T04:00:00+0000", "news_desk": "Business", "headline": {"print_headline": "Mylan Chief\u2019s Answers on EpiPen Frustrate House Panel", "main": "Mylan\u2019s Chief Is Chastised by Lawmakers Questioning EpiPen Pricing"}, "print_page": "3", "snippet": "Heather Bresch, the chief executive of Mylan, told a skeptical House panel that her company had struck a balance between price and access....", "_id": "57e2bab295d0e021d7987897", "slideshow_credits": null, "abstract": "Mylan chief executive Heather Bresch is interrogated by House Committee on Oversight and Government Reform over huge prices increases on allergy treatment EpiPen; panel expresses frustration as she defends firm's practices."}